Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

• Status: Recruiting
• Trial end date: 2024-02-01

Summary

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic HCT and determine whether the addition of Vorinostat to the standard preventive therapy (tacrolimus [or cyclosporine] / methotrexate) will reduce the incidence of graft versus host disease (GVHD) following allogeneic, myeloablative transplant in children, adolescents and young adults.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: University of Michigan Rogel Cancer Center
• Collaborator: National Institutes of Health (NIH)
• Treatments: Cyclosporine; Cyclosporins; Methotrexate; Tacrolimus; Vorinostat